drugset / Trial / NCT03480061

Dexmedetomidine to Reduce the Incidence of POCD After Open Cardiac Surgery

NCT03480061 ↗

Phase 4 Active not recruiting 90 enrolled Sunnybrook Health Sciences Centre
RandomizedParallel-groupDouble-blindPrevention

Summary

Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.

Timeline

Start
2018-08-09
Primary completion
2026-07
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.1 ug/kg —
Comparator Dexmedetomidine Other / unclassified 1 ug/kg —